Alibaba Group Holding Ltd. (NYSE:BABA) shares fell Wednesday after the e-commerce and cloud-computing company reported mixed fiscal fourth-quarter 2026 results, as strong revenue growth and accelerating AI momentum were overshadowed by a sharp decline in adjusted earnings. The company reported quarterly revenue of $35.28 billion, up 3% from a year earlier and slightly ahead of analyst estimates of...
Alibaba Group Holding Ltd. (NYSE:BABA) shares fell Wednesday after the e-commerce and cloud-computing company reported mixed fiscal fourth-quarter 2026 results, as strong revenue growth and accelerating AI momentum were overshadowed by a sharp decline in adjusted earnings. The company reported quarterly revenue of $35.28 billion, up 3% from a year earlier and slightly ahead of analyst estimates of $35.23 billion. Excluding the divested Sun Art and Intime businesses, revenue increased 11% on a li
Vishay Intertechnology press release ( VSH ): Q1 GAAP EPS of $0.05 beats by $0.02 . Revenue of $839.2M (+17.3% Y/Y) beats by $16.39M . 1Q 2026 book-to-bill of 1.34 with book-to-bill of 1.47 for semiconductors and 1.23 for passive components. Backlog at quarter end was 5.7 months. 2Q 2026 Outlook For the second quarter of 2026, management expects revenues in the range of $875 million and $905 milli...
Vishay Intertechnology press release ( VSH ): Q1 GAAP EPS of $0.05 beats by $0.02 . Revenue of $839.2M (+17.3% Y/Y) beats by $16.39M . 1Q 2026 book-to-bill of 1.34 with book-to-bill of 1.47 for semiconductors and 1.23 for passive components. Backlog at quarter end was 5.7 months. 2Q 2026 Outlook For the second quarter of 2026, management expects revenues in the range of $875 million and $905 million vs. consensus of $857.78M and a gross profit margin in the range of 22.0% +/- 50 basis points. More on Vishay Intertechnology Vishay Intertechnology: Be Cautious When A Stock Goes Vertical Vishay Intertechnology Q1 2026 Earnings Preview Seeking Alpha’s Quant Rating on Vishay Intertechnology Historical earnings data for Vishay Intertechnology Dividend scorecard for Vishay Intertechnology
Vinayak Jagtap/iStock via Getty Images India has more than doubled tariffs on gold and silver imports in an effort to ease pressure on the country's foreign exchange reserves and shore up the rupee as the Iran war drags on. The decision to raise the tariffs from 6% to 15% comes just days after Prime Minister Narendra Modi appealed to Indians to pause buying gold, avoid foreign travel and reduce fu...
Vinayak Jagtap/iStock via Getty Images India has more than doubled tariffs on gold and silver imports in an effort to ease pressure on the country's foreign exchange reserves and shore up the rupee as the Iran war drags on. The decision to raise the tariffs from 6% to 15% comes just days after Prime Minister Narendra Modi appealed to Indians to pause buying gold, avoid foreign travel and reduce fuel consumption. India, the world's second-largest consumer of precious metals, meets almost all of its gold consumption through imports. The tariff hike could help ease India's trade deficit and shield the rupee, which is among Asia's worst-performing currencies. Foreign investors are also increasingly pulling out of India's stock market, with the latest data showing that 2026 is set to be the worst year for outflows since 1993. The rupee ( INR:USD ) was trading at 95.58 to the U.S. dollar at the time of writing, recovering after notching a record low on Tuesday. The rupee has depreciated 6% against the greenback YTD. "While it is difficult to gauge the full impact, key implications could include: an impact on customer demand due to a further rise in gold (to the extent of a duty hike) and concerns about gold smuggling, especially from larger jewelers," Jefferies analysts said. India's stock market didn't move much after the tariff news, as higher oil prices and continued foreign outflows offset broader gains. The benchmark Nifty ( NIFTY ) and Sensex ( SENSEX ) indices ended 0.1% higher each on Wednesday after four sessions of losses. Gold and silver ETFs rallied as demand for these products could rise as physical imports get costlier, while shares of Indian jewelers fell. More on India NFTY: Structural Headwinds Persist (Still On Hold) INCO: Why Avoiding This ETF Remains A Better Choice India Is Great, But Be Careful When Everyone Agrees With The Thesis India more than doubles bullion import taxes to 15% as trade deficit widens
For setting yourself up for long-term investing success, simpler is usually better. By focusing on the one factor you can control -- costs and fees -- you significantly increase the odds of improving your portfolio's returns. But even if most actively managed funds didn't suffer from fee drag, there's little evidence that even professional money managers can consistently beat their benchmark. Over...
For setting yourself up for long-term investing success, simpler is usually better. By focusing on the one factor you can control -- costs and fees -- you significantly increase the odds of improving your portfolio's returns. But even if most actively managed funds didn't suffer from fee drag, there's little evidence that even professional money managers can consistently beat their benchmark. Over the past 20 years, 97% of all domestic funds underperformed their benchmarks. That's why keeping fees as low as possible and simply trying to match an index instead of beating it has proven so appealing. The Vanguard S&P 500 ETF (NYSEMKT: VOO) wouldn't be a surprising choice to beat actively managed funds this year, but its straightforward approach still makes it one of the best. Continue reading
The post Best CBD Oil Stocks by Chetan Shekar appeared first on Benzinga . Visit Benzinga to get more great content like this. After the legalization of marijuana in the U.S., many companies are actively engaged in the research, development and distribution of cannabis. Cannabidiol (CBD) is the non-psychoactive substance present within cannabis and its products such as CBD oil has had a major impa...
The post Best CBD Oil Stocks by Chetan Shekar appeared first on Benzinga . Visit Benzinga to get more great content like this. After the legalization of marijuana in the U.S., many companies are actively engaged in the research, development and distribution of cannabis. Cannabidiol (CBD) is the non-psychoactive substance present within cannabis and its products such as CBD oil has had a major impact on the health and wellness industry. Take a look at these CBD oil stock picks that are generating millions of dollars in revenue this year. Quick Look at the Best CBD Oil Stocks: Altria Jazz Pharmaceuticals Village Farm Inernational GrowGEneration Corp AbbVie Contents Quick Look at the Best CBD Oil Stocks: Overview: CBD Oil Stocks Best Online Brokers for CBD Oil Stock Features to Look for in CBD Oil Stock Don’t Panic, It’s Organic Frequently Asked Questions Overview: CBD Oil Stocks Since ancient times, cannabis has been used as a form of medicine and as a means to induce euphoria . Indian sages have also mentioned the medicinal use of marijuana in Vedic hymns of antiquity. However, President Richard Nixon banned the cultivation and sale of marijuana in the U.S. as part of his “war on drugs” campaign in 1970. It wasn’t until the Compassionate Use Act of 1996 was passed that California became the first state to legalize marijuana to treat people with severe or chronic diseases. As of 2022, 37 states in the U.S. have legalized the medical use of marijuana and 18 states have legalized the recreational use of marijuana. According to a recent report by the New Frontier Data, the legal sale of cannabis could reach $30 billion by 2025. Due to such high potential to earn profits, alcohol companies have started to invest big in CBD oil companies. Constellation Brands Inc. (NYSE: STZ) has invested billions in Canopy Growth Corp. (NYSE: CGC). Molson Coors (NYSE: TAP) invested billions in Hexo (TSX: HEXO). Budweiser (NYSE: BUD) entered a joint venture to develop non-alcoholic CBD dri...
SweetBunFactory/iStock via Getty Images The market is still undervaluing the potential for Advanced Micro Devices ( AMD ) to grow much bigger when Helios and MI450s take off from the hyperscalers' side. My bullish call has played out exceptionally well so far and it’s not just about becoming the second GPU provider anymore. AMD will turn into an AI ecosystem platform company where all components, ...
SweetBunFactory/iStock via Getty Images The market is still undervaluing the potential for Advanced Micro Devices ( AMD ) to grow much bigger when Helios and MI450s take off from the hyperscalers' side. My bullish call has played out exceptionally well so far and it’s not just about becoming the second GPU provider anymore. AMD will turn into an AI ecosystem platform company where all components, CPUs, GPUs and rack scale solutions, are complementing each other. If execution goes as planned and the EPS reaches $15 by FY2027, then $600 per share no longer looks ambitious but quite realistic. AI Story Is Now Shifting From Participation To Scale AMD rally is difficult to dismiss as just momentum. What was originally a turnaround from excessive pessimism has transformed into something fundamentally different. Stock is no longer priced based on AMD ability to play the role in AI infrastructure deployments, this has been solved. Instead, the question is about the degree and level to which AMD could leverage its position as a vendor once deployments move beyond the accelerator bottleneck towards full system scaling. This is an important nuance since the fundamental thesis for AMD has shifted entirely. When stock was priced between $90 and $150, it was a textbook example of an asymmetric recovery trade. AMD's CPUs have always been a high conviction trade and the stock was priced based on risk of GPU revenue while providing massive upside from server business. As AMD rallied close to $460, the thesis has shifted. Personally, I no longer see AMD's stock priced on current earnings. Rather, it reflects confidence on AMD's ability to deliver a specific business model in 2027 or even 2028. Data by YCharts Why I began viewing AMD as a structural shift following Q1 2026 has little to do with beating the earnings estimates themselves. In Q1, AMD managed to increase its revenue by 38% y/y to $10.3 billion and produce free cash flow of more than $2.6 billion, a record high for the com...
SweetBunFactory/iStock via Getty Images The market is still undervaluing the potential for Advanced Micro Devices ( AMD ) to grow much bigger when Helios and MI450s take off from the hyperscalers' side. My bullish call has played out exceptionally well so far and it’s not just about becoming the second GPU provider anymore. AMD will turn into an AI ecosystem platform company where all components, ...
SweetBunFactory/iStock via Getty Images The market is still undervaluing the potential for Advanced Micro Devices ( AMD ) to grow much bigger when Helios and MI450s take off from the hyperscalers' side. My bullish call has played out exceptionally well so far and it’s not just about becoming the second GPU provider anymore. AMD will turn into an AI ecosystem platform company where all components, CPUs, GPUs and rack scale solutions, are complementing each other. If execution goes as planned and the EPS reaches $15 by FY2027, then $600 per share no longer looks ambitious but quite realistic. AI Story Is Now Shifting From Participation To Scale AMD rally is difficult to dismiss as just momentum. What was originally a turnaround from excessive pessimism has transformed into something fundamentally different. Stock is no longer priced based on AMD ability to play the role in AI infrastructure deployments, this has been solved. Instead, the question is about the degree and level to which AMD could leverage its position as a vendor once deployments move beyond the accelerator bottleneck towards full system scaling. This is an important nuance since the fundamental thesis for AMD has shifted entirely. When stock was priced between $90 and $150, it was a textbook example of an asymmetric recovery trade. AMD's CPUs have always been a high conviction trade and the stock was priced based on risk of GPU revenue while providing massive upside from server business. As AMD rallied close to $460, the thesis has shifted. Personally, I no longer see AMD's stock priced on current earnings. Rather, it reflects confidence on AMD's ability to deliver a specific business model in 2027 or even 2028. Data by YCharts Why I began viewing AMD as a structural shift following Q1 2026 has little to do with beating the earnings estimates themselves. In Q1, AMD managed to increase its revenue by 38% y/y to $10.3 billion and produce free cash flow of more than $2.6 billion, a record high for the com...
The old market saying tells investors to “Sell in May and go away,” parking proceeds until the historically stronger fall months. The seasonal calendar is rarely a good investment thesis on its own. Applied to Intel (NASDAQ: INTC), however, it offers a convenient excuse to confront a more important question: what do you do with ... Intel Has Tripled in 2026. The Sell in May Case for the Year’s Big...
The old market saying tells investors to “Sell in May and go away,” parking proceeds until the historically stronger fall months. The seasonal calendar is rarely a good investment thesis on its own. Applied to Intel (NASDAQ: INTC), however, it offers a convenient excuse to confront a more important question: what do you do with ... Intel Has Tripled in 2026. The Sell in May Case for the Year’s Biggest Comeback Story
Wengen Ling/E+ via Getty Images Note: I have covered Microvast Holdings, Inc. ( MVST ) ( MVSTW ), or “Microvast,” previously, so investors should view this as an update to my earlier articles on the company. Eight months ago, I downgraded shares of lithium-ion battery manufacturer Microvast from “Hold” to “Sell” due to declining backlog levels and elevated valuation. This turned out to be a good c...
Wengen Ling/E+ via Getty Images Note: I have covered Microvast Holdings, Inc. ( MVST ) ( MVSTW ), or “Microvast,” previously, so investors should view this as an update to my earlier articles on the company. Eight months ago, I downgraded shares of lithium-ion battery manufacturer Microvast from “Hold” to “Sell” due to declining backlog levels and elevated valuation. This turned out to be a good call, as the stock has lost more than 60% of its value in recent quarters: Barchart.com After the close of Monday's regular session, the company reported disappointing Q1/2026 results, with sales coming in well below expectations, negative adjusted EBITDA, and sizeable cash usage: Company Press Releases/Regulatory Filings In the press release, management attributed the weak performance to a number of issues: Evolving regulatory and geopolitical dynamics, particularly in South Korea and India. Demand is shifting towards lower-cost products in India. Persistent OEM BEV platform ramp-up delays in the transportation and mining sectors. Sales were down materially across all regions: Company Presentation In South Korea, the market continues to be disrupted by new regulations and lower customer demand following a series of high-profile fires in recent years. In India, a combination of stricter safety mandates and unfavorable shifts in the subsidy regime has weighed on the company's sales. With subsidies now capped and requiring at least 50% local content, customers have shifted to less expensive, domestically manufactured products. As a result, APAC sales were down 66% on a year-over-year basis. In the United States, sales were down a whopping 96% after Microvast's largest customer pulled forward product deliveries into late 2025 due to tariff-related considerations. Even Europe was down by almost 30% as OEMs continued to delay platform launches and production ramp-ups. The company recorded a $5.5 million adjusted EBITDA loss, down $34.0 million on a year-over-year basis. The backl...
Advanced Energy Industries ( AEIS ) plans to offer $1B aggregate principal amount of Convertible Senior Notes due 2031 in a private offering. The firm also expects to grant the initial purchasers of the notes an option to purchase up to an additional $150M of the notes. Advanced Energy said it plans to use part of the offering proceeds to cover the cost of capped call transactions tied to the deal...
Advanced Energy Industries ( AEIS ) plans to offer $1B aggregate principal amount of Convertible Senior Notes due 2031 in a private offering. The firm also expects to grant the initial purchasers of the notes an option to purchase up to an additional $150M of the notes. Advanced Energy said it plans to use part of the offering proceeds to cover the cost of capped call transactions tied to the deal. The company will also use some proceeds, along with newly issued common shares, to exchange certain 2.50% convertible notes due 2028. The remaining proceeds will be used for general corporate purposes, including potentially paying off the rest of the 2028 convertible notes. AEIS shares fell -3.1% premarket on Wednesday. More on Advanced Energy Advanced Energy: Data Center Revenue Doubles Advanced Expectations The Biggest Challenge For Advanced Energy Industries Right Now Advanced Energy Industries, Inc. 2026 Q1 - Results - Earnings Call Presentation Advanced Energy forecasts low-to-mid-20% 2026 revenue growth as it targets over 43% gross margin Advanced Energy Non-GAAP EPS of $2.09 beats by $0.11, revenue of $511M beats by $5.22M
MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended April 4, 2026.
MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended April 4, 2026.
Milestone Pharmaceuticals press release ( MIST ): Q1 GAAP EPS of -$0.20 misses by $0.39 . Revenue of $0.24M misses by $37.4M . As of March 31, 2026, Milestone had cash, cash equivalents, and short-term investments of $184.2 million, compared to $106.0 million on December 31, 2025. The company currently expects its cash, cash equivalents and short-term investments to be sufficient to cover operatin...
Milestone Pharmaceuticals press release ( MIST ): Q1 GAAP EPS of -$0.20 misses by $0.39 . Revenue of $0.24M misses by $37.4M . As of March 31, 2026, Milestone had cash, cash equivalents, and short-term investments of $184.2 million, compared to $106.0 million on December 31, 2025. The company currently expects its cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above. More on Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals Historical earnings data for Milestone Pharmaceuticals Financial information for Milestone Pharmaceuticals
Avalo Therapeutics press release ( AVTX ): Q1 GAAP EPS of -$0.98 beats by $0.05 . Cash, cash equivalents and short-term investments were $82.0 million as of March 31, 2026. Net cash used in operating activities was $17.7 million for the three months ended March 31, 2026. Subsequent to March 31, 2026, the Company completed an underwritten public offering of its common stock and pre-funded warrants ...
Avalo Therapeutics press release ( AVTX ): Q1 GAAP EPS of -$0.98 beats by $0.05 . Cash, cash equivalents and short-term investments were $82.0 million as of March 31, 2026. Net cash used in operating activities was $17.7 million for the three months ended March 31, 2026. Subsequent to March 31, 2026, the Company completed an underwritten public offering of its common stock and pre-funded warrants for net proceeds of approximately $405.0 million. Our current cash, cash equivalents, and short-term investments are expected to fund operations into 2029. More on Avalo Therapeutics Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data Avalo Therapeutics prices $375M public offering; shares jump Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data for Avalo Therapeutics Financial information for Avalo Therapeutics